跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
TECENTRIQ - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
TECENTRIQ
Authorized
STANDARD
TECENTRIQ
Hoffmann-La Roche Limited
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
6c08c9ebb6f6585e
Company
Hoffmann-La Roche Limited
Type
Standard
Approval Details
Approval Id
6c08c9ebb6f6585e
Drug Approval Canada Name
TECENTRIQ
Product Name
TECENTRIQ
Status
Marketed
Status Date
2019-10-16
Original Market Date
2019-10-16
Din
02492393
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Intravenous
Schedule
Schedule D , Prescription
Ahfs
10:00.00
Atc Original
L01FF05 ATEZOLIZUMAB
Atc Name
l 01 ff 05
Aig Number
0158930001
Company Name
Hoffmann-La Roche Limited
Company Address
7070 Mississauga Road, Mississauga, Ontario, Canada, L5N 5M8
Active Ingredients
ATEZOLIZUMAB
840 MG / 14 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
6c08c9ebb6f6585e
Type
Standard
Back to Health Canada Approvals